Inquiry Basket
Loading ......
Folate receptor-alpha (FRα) is a membrane-associated protein that mediates cellular uptake of folate through receptor-mediated endocytosis. One of its most clinically relevant characteristics is its highly selective expression pattern: FRα is strongly overexpressed in a range of epithelial-derived cancers, including ovarian, breast, lung, and kidney cancers, while remaining minimally expressed in most normal tissues. This differential expression creates a highly favorable therapeutic window for targeted drug delivery strategies.
Another defining feature of FRα is its exceptionally high affinity for folate, with a dissociation constant (Kd) in the range of ~10-10M. This tight binding interaction supports stable ligand engagement even in complex biological environments, making FRα one of the most attractive targets for precision oncology applications where specificity and retention are critical for therapeutic success.
High-affinity targeting strategies for FRα primarily rely on two complementary approaches: monoclonal antibody-based systems and folate ligand conjugation. Both strategies aim to enhance selectivity and improve intracellular delivery efficiency.
Monoclonal antibodies directed against FRα, including antibody fragments and engineered derivatives, have been widely applied in tumor imaging and immunotherapy. In clinical and preclinical studies, these antibodies have demonstrated strong targeting performance, particularly in ovarian cancer, where FRα expression is frequently elevated. Their ability to bind selectively to tumor-associated receptors enables improved localization of therapeutic payloads and reduced off-target exposure.
In parallel, folate ligand conjugation strategies exploit folate's natural binding affinity for FRα. Chemical modification of folate, particularly at the γ-carboxyl group, preserves receptor recognition while enabling conjugation to drugs, nanoparticles, or imaging probes. This dual strategy—antibody- and ligand-based targeting—provides flexibility in designing delivery systems tailored to different therapeutic and diagnostic needs.
Accurate monitoring of FRα-mediated drug delivery is essential for evaluating targeting efficiency, biodistribution, and therapeutic response. Several complementary technologies are widely used for this purpose.
Fluorescence imaging provides a non-invasive and highly sensitive approach for tracking FRα expression and drug delivery in vivo. Probes such as IVISense™ Folate Receptor 680 are specifically designed to bind FRα with high specificity. When used with in vivo imaging systems, these probes enable real-time visualization and quantitative assessment of receptor distribution and targeting efficiency. This allows researchers to monitor drug localization dynamically over time without the need for invasive sampling.
Radiolabeled folate analogs such as 99mTc-EC20 offer another powerful modality for FRα-targeted imaging. This compound binds selectively to FR-positive tumors and can be detected using nuclear imaging techniques. Clinical studies have demonstrated both the safety and diagnostic effectiveness of this agent, particularly in identifying FRα-expressing lesions and guiding patient stratification for targeted therapies.
At the cellular and tissue level, high-affinity antibodies such as MOv19 and SP8166 are widely used to quantify FRα expression and evaluate drug delivery efficiency. Flow cytometry enables precise quantification of receptor-positive cell populations, while immunofluorescence and immunohistochemistry provide spatial visualization within tumor tissues.
For example, the SP8166 antibody has demonstrated strong binding affinity to human FolRα, with a KD of approximately 2.3 nmol/L measured via SPR analysis. Similarly, the fully human IgG1 antibody AFRA hIgG1, derived from MOv19, has shown promising antitumor activity, highlighting the translational potential of antibody engineering in FRα-targeted systems.
The most advanced application of FRα-targeted delivery systems is antibody-drug conjugates (ADCs), which combine the specificity of antibodies with the cytotoxic potency of chemotherapeutic agents.
IMGN853 is one of the most well-known FRα-targeting ADCs, demonstrating strong antitumor activity in FRα-positive malignancies. Its ability to selectively deliver cytotoxic payloads to tumor cells has positioned it as a key candidate in targeted ovarian cancer therapy.
Another important candidate is STRO-002, developed by Sutro Biopharma. This homogeneous ADC is currently undergoing clinical evaluation for ovarian and endometrial cancers. It utilizes optimized antibodies such as SP8166, which exhibit high affinity binding, efficient internalization, and strong thermal stability—properties essential for robust clinical performance.
Early work based on the MOv19 monoclonal antibody has also contributed significantly to ADC development. MOv19-derived constructs have enabled the creation of chimeric antibody-drug conjugates, many of which are currently in clinical trials, underscoring the foundational role of this antibody in FRα-targeted therapeutic innovation.
The effectiveness of FRα-targeted systems depends on a well-defined biological transport mechanism. Upon binding to folate or antibody-conjugated ligands, FRα undergoes receptor-mediated endocytosis, internalizing the therapeutic complex into the cell.
Once inside endosomal compartments, the mildly acidic environment triggers conformational changes in FRα. These changes significantly reduce its binding affinity for folate, promoting ligand release within the cell. This pH-sensitive dissociation mechanism is critical for ensuring that therapeutic payloads are efficiently released at the intracellular level rather than remaining bound to the receptor.
Targeted delivery systems are designed to exploit this natural trafficking pathway, enabling controlled intracellular release of drugs precisely where they are needed.
Recent advancements in drug delivery have focused on integrating FRα targeting strategies with nanotechnology to further enhance therapeutic performance.
Folate-modified polymer conjugates are increasingly used for gene delivery systems and lipid-based drug carriers. These systems improve stability, circulation time, and cellular uptake efficiency.
Dual-functional liposomes, modified with both folate and biotin, have been developed to enhance anticancer drug delivery and improve tumor penetration. Additionally, glutathione (GSH)-responsive nanoparticles provide stimulus-responsive release mechanisms, allowing drugs to be released specifically within the reductive intracellular environment of tumor cells.
These nanotechnology integrations significantly expand the versatility and effectiveness of FRα-targeted systems.
FRα-targeted drug delivery systems are primarily applied in cancers with high receptor expression profiles. Ovarian cancer represents the most prominent indication, with over 90% of cases showing FRα positivity. This makes it one of the most important clinical targets for FRα-based therapies.
Other relevant malignancies include breast cancer, lung cancer, kidney cancer, and endometrial cancer. In these diseases, FRα expression levels vary but are often sufficient to support targeted therapeutic approaches, particularly in advanced or treatment-resistant cases.
High-affinity antibodies play a central role in monitoring and enabling FRα-mediated drug delivery. Through advanced imaging modalities such as fluorescence imaging, radionuclide scanning, flow cytometry, and immunohistochemistry, researchers can precisely track receptor expression and therapeutic distribution in real time.
The field has progressed rapidly from basic receptor biology to advanced clinical applications, with multiple FRα-targeted antibody-drug conjugates now in clinical trials. Continued integration of antibody engineering, imaging technologies, and nanomedicine platforms is expected to further improve targeting accuracy and therapeutic outcomes in FRα-positive cancers.
FRα is highly overexpressed in several epithelial cancers such as ovarian, breast, lung, and kidney cancers, while showing minimal expression in most normal tissues. This strong differential expression enables highly selective targeting, reducing damage to healthy cells and improving therapeutic precision. Its extremely high affinity for folate also enhances binding stability, making it an ideal receptor for targeted drug delivery systems.
High-affinity antibodies bind specifically to FRα on cancer cells and serve as delivery vehicles for imaging agents or therapeutic payloads. They improve targeting accuracy, enhance cellular uptake through receptor-mediated endocytosis, and allow researchers to monitor drug distribution. Antibodies such as MOv19 and SP8166 have demonstrated strong binding performance and are widely used in both research and clinical development.
FRα expression is typically monitored using multiple complementary technologies. Fluorescence imaging probes like IVISense Folate Receptor 680 enable non-invasive visualization, while radionuclide tracers such as 99mTc-EC20 allow nuclear imaging of tumors. At the cellular level, flow cytometry and immunohistochemistry using high-affinity antibodies provide detailed quantification and spatial mapping of FRα expression.
ADCs are engineered molecules that combine monoclonal antibodies targeting FRα with cytotoxic drugs. Once the antibody binds to FRα on cancer cells, the complex is internalized and releases the drug inside the cell, killing the tumor. Examples include IMGN853 and STRO-002, both of which are being evaluated in clinical trials for ovarian and endometrial cancers.
FRα-targeted therapies are most effective in cancers with high receptor expression. Ovarian cancer is the primary indication, with over 90% of cases showing FRα positivity. Other cancers that may benefit include breast cancer, lung cancer, kidney cancer, and endometrial cancer, especially in advanced or treatment-resistant stages where targeted strategies are needed.
References
| Target | Cat. No. | Product Name | Host | Application | |
| Vitamin B12 | HMABPY073 | RHA™ anti-Vitamine B12 monoclonal antibody, clone VB12 | Mouse | ELISA, LFIA | Inquiry |
| DPATB-H83238 | Anti-Vitamin B12 polyclonal antibody | Rabbit | ELISA | Inquiry | |
| Folate | DMAB3387 | Anti-Folate monoclonal antibody, clone A9/34 | Mouse | RIA, EIA | Inquiry |
| DMAB3388 | Anti-Folate monoclonal antibody, clone C763F | Mouse | cELISA | Inquiry | |
| DMAB3390 | Anti-Folate monoclonal antibody, clone C765F | Mouse | cELISA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| Vitamin B12 | DAG3037 | Vitamin B12 [BSA] | BSA | N/A | Inquiry |
| DAG3038 | Vitamin B12 [HRP] | HRP | N/A | Inquiry | |
| DAG3039 | Vitamin B12 [KLH] | KLH | N/A | Inquiry | |
| DISNJ01 | Vitamin B12 Standard Solution | N/A | ELISA | Inquiry | |
| DAGA-068B | Vitamine B12 [BSA] | BSA | LFIA | Inquiry | |
| DAGA-073K | Vitamine B12 [KLH] | KLH | Immunogen | Inquiry | |
| DAGT5413-HRP | Vitamine B12 [HRP] | HRP | ELISA | Inquiry | |
| DAG271S | Vitamin B12 [HSA] | HSA | ELISA | Inquiry | |
| DAG545S | Vitamin B12 [HSA-Biotin] | HSA-Biotin | ELISA | Inquiry | |
| DAG-WT2686 | Vitamin B12 control | Unconjugated | Immunoassays | Inquiry | |
| VB12 | DAGA-068O | Vitamin B12 [OVA] | OVA | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Sample | |
| Vitamin B12 | DEIA280 | Vitamin B12 ELISA Kit | 96T | N/A | Quantitative | food | Inquiry |
| DEIA2541 | Food Vitamin B12 ELISA Kit | 96T | Quantitative | multivitamin tablets, capsules, multivitamin juices, multivitamin jam, grain products, multivitamin sweets | Inquiry | ||
| DEIASL091 | Vitamin B12 ELISA Kit | 96T | Quantitative | cereals, milk, milk powder | Inquiry | ||
| DEIACL6 | CDSimple™ Vitamin B12 Chemiluminescent ELISA Kit | 96T, 192T | Quantitative | Serum | Inquiry | ||
| VB12 | DEIA2451 | Vitamin B12 ELISA Kit | 96T | N/A | Quantitative | food | Inquiry |
| DEIA-JY2109 | Vitamin B12 (Cobalamin) ELISA Kit | 96T | N/A | Quantitative | Food and dietary supplements. | Inquiry | |
| DEIA280NS | Vitamin B12 (Cobalamin) Plate Kit | 96T | N/A | Quantitative | Food | Inquiry | |
| Folic acid | DEIAH4170 | Human 5-MTHF(5-Methyltetrahydrofolate) ELISA Kit | 96T | Human | Quantitative | Serum, plasma, tissue homogenates and other biological fluids | Inquiry |
| Folate | DEIACL2 | CDSimple™ Folate & Vitamin B12 Chemiluminescent ELISA Kit | 96T, 192T | Quantitative | Serum, Plasma | Inquiry | |
| DEIACL4 | CDSimple™ Folate Chemiluminescent ELISA Kit | 96T, 192T | Quantitative | Serum | Inquiry |
Loading ......
